Evidence map›Paper›PMID 36816927›Full record

ArticleFrontiers in oncology2023

Case Report: Disease progression of renal cell carcinoma containing a novel putative pathogenic

Almas Dawood, Suzanne MacMahon, My-Anh Tran Dang, Maxine G B Tran, Axel Bex, Ekaterini Boleti, Soha El Sheikh

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Almas DawoodDepartment of Cellular Pathology, Royal Free London Foundation Trust, London, United Kingdom.
Suzanne MacMahonThe Centre for Molecular Pathology, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom.
My-Anh Tran DangDepartment of Cellular Pathology, Royal Free London Foundation Trust, London, United Kingdom.
Maxine G B TranSpecialist Centre for Kidney Cancer, Royal Free Hospital, London, United Kingdom.
Axel BexSpecialist Centre for Kidney Cancer, Royal Free Hospital, London, United Kingdom.
Ekaterini BoletiSpecialist Centre for Kidney Cancer, Royal Free Hospital, London, United Kingdom.
Soha El SheikhDepartment of Cellular Pathology, Royal Free London Foundation Trust, London, United Kingdom.
University College London · GBRoyal Free London NHS Foundation Trust · GBRoyal Marsden NHS Foundation Trust · GBThe Royal Free Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal cell carcinoma still carries a poor prognosis despite therapeutic advancements. Detection of genetic mutations is vital in improving our understanding of this disease as well as potential role in targeted therapy. Here we present a case of a 49 year old man with an aggressive renal cell carcinoma bearing a novel pathogenic

Indexed as

fusionimmunotherapyKAT6AmutationNrg1renal cell carcinoma

Identifiers

PMID36816927
PMCPMC9932956
OpenAlexW4318983408

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.